The Farr Institute International Advisory Board (IAB) is represented by 12 esteemed and internationally renowned scientists, healthcare professionals and industry experts.
This influential group of leaders from around the globe review The Farr Institute’s research activities, guide future developments, advise on global and strategic direction and facilitate discussions with thought-leaders and policy makers in the field of health informatics research. The Board’s combined experience, knowledge, and expertise supports The Farr Institute and its network in identifying strategic Research and Development opportunities and new initiatives for the development of expertise in the United Kingdom and internationally.
The IAB is an independent body and does not hold executive powers. Members of the Board hold a three year renewable term and meet annually with The Farr Institute Executive Group in December.
Governance, ethics and matters of public interest
Business model development, sustainability and routes to engagement with industry and healthcare stakeholders
Future research trends, impact and growth opportunities
Progress against other institutions and agencies, nationally and internationally
Professor Nancy Pedersen (Chair)
Professor Nancy Pedersen is Director of Lifegene project and Professor of Genetic Epidemiology, Karolinska Institute.
The Behaviour Genetics Association recently awarded Professor Pedersen the Dobzhansky Award for lifetime accomplishments in the field of behavioural genetics, reflecting her position as a leading authority in genetic epidemiology. Educated in the United States in Minnesota and Colorado, Professor Pedersen’s has been working from the prestigious Karolinska Institutet for many years.
Mr Ian Crichton
Ian Crichton joined Serco in March 2016 as Managing Director for its UK Health business. Serco provides essential services in support of the health sector and Ian’s experience of both the NHS and the private sector make him well placed to lead and grow this core capability for Serco.
Ian has over 20 years of experience in international business, specifically in managing large strategic agendas. Before joining NHS National Services Scotland as Chief Executive in 2007, he was Director of Commercial Operations at Suunto, based in Helsinki, and spent many years working for Gillette in a variety of senior management positions worldwide. Over the last six years, Ian has led NSS through a significant programme of modernisation whilst continuing to deliver a diverse range of specialist and shared national services, in support of the Health Service in S
Professor Georges De Moor
Professor De Moor is head of the Department of Medical Informatics and Statistics at the State University of Ghent, and head of Clinical Pathology Laboratory of the St-Elisabeth Hospital in Zottegem.
He chairs a number of national government committees in health and social affairs, as well as professional organisations in Belgium and beyond. He was Founding Chairman of CEN/TC251, the official standardisation committee in health informatics in Europe, and has founded a number of companies based on his research. In 2004, he was elected President of the European Institute for Health Records (EuroRec).
Mr Simon Denegri
Simon Denegri is National Director for Patients and the Public at the National Institute for Health Research (NIHR), and Chair of INVOLVE – the national advisory group for the promotion and support of public involvement in research funded by NIHR.
Prior to this he served as Chief Executive of the 127-strong Association of Medical Research Charities (AMRC) , Director of Corporate Communications at the Royal College of Physicians of London from 2003 to 2006, and at the Alzheimer’s Society (UK) becoming its first head of public affairs.
Professor Isaac Kohane
Isaac Kohane, MD, PhD is the inaugural Chair of the Department of Biomedical Informatics at Harvard Medical School.
He develops and applies computational techniques to address disease at multiple scales: From whole healthcare systems as “living laboratories” to the functional genomics of neurodevelopment with a focus on autism. Kohane’s i2b2 project is currently deployed internationally to over 120 major academic health centers to drive discovery research in disease and pharmacovigilance (including providing evidence on drugs which ultimately contributed to “black box”ing by the FDA). Dr. Kohane has published several hundred papers in the medical literature and authored a widely used book on Microarrays for an Integrative Genomics. He is a member of the Institute of Medicine and the American Society for Clinical Investigation.
Dr William Lowrance
William W. Lowrance, Ph.D., is a consultant in health research ethics and policy, based in La Grande Motte, France.
After earning a doctorate from The Rockefeller University in the life sciences in 1971, he shifted his attention to the social aspects of science, technology, and medicine. Bill has been a faculty member or fellow, teaching and conducting research on health policy, environmental policy and risk decision making at Harvard, Stanford, and Rockefeller Universities. He served as the Director of the Life Sciences and Public Policy Program of Rockefeller University, and as the Executive Director of the International Medical Benefit/Risk Foundation, headquartered in Geneva. He has served on many advisory committees and governing boards. His books include Of Acceptable Risk: Science and the Determination of Safety and Modern Science and Human Values.
Professor Michael Parker
Michael Parker is Professor of Bioethics and Director of the Ethox Centre, University of Oxford.
Michael’s main research interest is in the ethics of collaborative global health research. Together with partners at the Wellcome Trust Major Overseas Programmes in Vietnam, Malawi, Thailand-Laos, Kenya, and South Africa he co-ordinates the Global Health Bioethics Network – a programme to carry out ethics research and build ethics capacity. Michael also leads the ethics programme of the Malaria Genomic Epidemiology Network which carries out genomic research into severe malaria in childhood at more than 30 sites in 21 countries.
Professor Dan Roden
Professor Roden is Professor of Medicine and Pharmacology at the Vanderbilt University School of Medicine, in addition to being Assistant Vice Chancellor for Personalised Medicine.
He holds the William Stokes Chiar of Experimental Therapeutics and is Director of the Oates Institute. He is the American Coordinator and Nashville Centre Director of the Fondation Leducq for Sudden Cardiac Death, and runs a lab researching factors that determine ion channel gene expression in cardiac tissue. Approaches include identification of new genes, identification of DNA polymorphisms and characterization of their functional effects on disease and drug responses, and modulation of expression in cultured heart cells (e.g. by antisense) and gene knockout in mice.
Dr John Speakman
John Speakman is Senior Director for Research Informaion Technology at New York University Langone Medical Centre.
John is responsible for the development and implementation of NYU Langone Medical Centre’s research related information technology projects including administration, clinical, basic science and computational. Before this he spent several years in Senior roles at the National Cancer Institute, where he oversaw the informatics programs that support, and form part of, the United States national cancer research enterprise serving as a liaison between government, academic and commercial enterprise and overseeing a staff of federal employees and contractors as well as an eight-figure annual budget.
Professor Graham Spittle CBE
Professor Graham Spittle is Chief Technology Officer and Vice President, Software Group at IBM.
Prior to taking up this position in 2010, Graham Spittle held several senior executive positions within IBM: Vice President, Software UKI (UK & Ireland); Vice President, Worldwide Integration Development; Director of the IBM Hursley Laboratory in the United Kingdom, and Director of MQ Development. Graham joined IBM in 1985 at the Hursley Laboratory. His roles have included development and strategy responsibility for major IBM products such as CICS and Business Integration Middleware (including the MQSeries family), as well as Business Development responsibilities. From 1995 to 1997 Graham was on international assignment in Software Group located in New York.
Mr Matthew Swindells
National Director: Operations and Information, NHS England.
Mr Bart Vannieuwenhuyse
In 1985, Bart joined Janssen Pharmaceutica as a clinical trial monitor. In the course of his career with Janssen, Bart has held a variety of marketing and sales positions, both at local operating company level (e.g. the Netherlands) and at international level. While in the Netherlands he was one of the pioneers that started “Healthy Solutions” a J&J daughter company that focused on developing integrated services in the healthcare field. Later, he was in the core team that developed the initial CRM approach for Janssen EMEA. Between 1999 and 2003, Bart spent 4 years in the IM department of Janssen Pharmaceutica in the US, where he was responsible for the e-business initiatives and for the overall IM technical architecture. Bart joined the EMEA CRM Center of Excellence in April 2003, where he prepared the CRM Roadmap for the short to mid-term.
In 2009 Bart was instrumental in developing a new customer-orientation project for Janssen Europe. In 2011 Bart joined the Janssen R&D group to focus on external eHealth / Health Information projects with external partners. Currently, Bart is coordinator of the EMIF (European Medical Information Framework) project, an IMI (Innovative Medicine Initiative) funded project.
Bart holds a MSc degree in Biology from the University of Ghent (Belgium) and a MBA/MBI degree from the Erasmus University Rotterdam (Netherlands).